维普中文期刊产品整合服务
723篇 您的检索式:作者名="Philippe B"
    题名 作者 年代 出处 被引量
1Epidural anesthesia improves pancreatic perfusion and decreases the severity of acute pancreatitis显示文摘AIM: To study the safety of epidural anesthesia(EA),its effect on pancreatic perfusion and the outcome of patients with acute pancreatitis(AP).METHODS: From 2005 to August 2010,patients with predicted severe AP [Ranson score ≥ 2,C-reactive protein > 100 or necrosis on computed tomography(CT)] were prospectively randomized to either a group receiving EA or a control group treated by patientcontrolled intravenous analgesia. Pain management was evaluated in the two groups every eight hours using the visual analog pain scale(VAS). Parameters for clinical severity such as length of hospital stay,use of antibiotics,admission to the intensive care unit,radiological/clinical complications and the need for surgical necrosectomy including biochemical data were recorded. A CT scan using a perfusion protocol was performed on admission and at 72 h to evaluate pancreatic blood flow. A significant variation in blood flow was defined as a 20% difference in pancreatic perfusion between admission and 72 h and was measured in the head,body and tail of the pancreas.RESULTS: We enrolled 35 patients. Thirteen were randomized to the EA group and 22 to the control group. There were no differences in demographic characteristics between the two groups. The Balthazar radiological severity score on admission was higher in the EA group than in the control group(mean score 4.15 ± 2.54 vs 3.38 ± 1.75,respectively,P = 0.347) and the median Ranson scores were 3.4 and 2.7 respectively(P = NS). The median duration of EA was 5.7 d,and no complications of the epidural procedure were reported. An improvement in perfusion of the pancreas was observed in 13/30(43%) of measurements in the EA group vs 2/27(7%) in the control group(P = 0.0025). Necrosectomy was performed in 1/13 patients in the EA group vs 4/22 patients in the control group(P = 0.63). The VAS improved during the first ten days in the EA group compared to the control group(0.2 vs 2.33,P = 0.034 at 10 d). Length of stay and mortality were not statistically different between the 2 groups(26 d vs 30 d,P = 0.65,and 0% for both respectively).CONCLUSION: Our study demonstrates that EA increases arterial perfusion of the pancreas and improves the clinical outcome of patients with AP.Samira M Sadowski Axel Andres Philippe Morel Eduardo Schiffer Jean-Louis Frossard Alexandra Platon Pierre-Alexandre Poletti Leo Bühler 2015World Journal of Gastroenterology2015,21,43:21
2Rescue associating liver partition and portal vein ligation for staged hepatectomy after portal embolization: Our experience and literature review显示文摘AIM To report a single-center experience in rescue associating liver partition and portal vein ligation for staged hepatectomy(ALPPS), after failure of previous portal embolization. We also performed a literature review.METHODS Between January 2014 and December 2015, every patient who underwent a rescue ALPPS procedure in Toulouse Rangueil University Hospital, France, was included. Every patient included had a project of major hepatectomy and a previous portal vein embolization(PVE) with insufficient future liver remnant to body weight ratio after the procedure. The ALPPS procedure was performed in two steps(ALPPS-1 and ALPPS-2), separated by an interval phase. ALPPS-2 was done within 7 to 9 d after ALPPS-1. To estimate the FLR, a computed tomography scan examination was performed 3 to 6 wk after the PVE procedure and 6 to 8 d after ALPPS-1. A transcystic stent was placed during ALPPS-1 and remained opened duringthe interval phase, in order to avoid biliary complications. Postoperative liver failure was defined using the 50-50 criteria. Postoperative complications were assessed according to the Dindo-Clavien Classification.RESULTS From January 2014 to December 2015, 7 patients underwent a rescue ALPPS procedure. Median FLR before PVE, ALPPS-1 and ALPPS-2 were respectively 263 cc(221-380), 450 cc(372-506), and 660 cc(575-776). Median FLR/BWR before PVE, ALPPS-1 and ALPPS-2 were respectively 0.4%(0.3-0.5), 0.6%(0.5-0.8), and 1%(0.8-1.2). Median volume growth of FLR was 69%(18-92) after PVE, and 45%(36-82) after ALPPS-1. The combination of PVE and ALPPS induced a growth of median initial FLR of +408 cc(254-513), leading to an increase of +149%(68-199). After ALPPS-2, 4 patients had stage Ⅰ-Ⅱ complications. Three patients had more severe complications(one stage Ⅲ, one stage Ⅳ and one death due to bowel perforation). Two patients suffered from postoperative liver failure according to the 50/50 criteria. None of our patients developed any biliary complication during the ALPPS procedure.CONCLUSION Rescue ALPPS may be an alternative after unsuccessful PVE and could allow previously unresectable patients to reach surgery. Biliary drainage seems to reduce biliary complications.Charlotte Maulat Antoine Philis Bérénice Charriere Fatima-Zohra Mokrane Rosine Guimbaud Philippe Otal Bertrand Suc Fabrice Muscari 2017World Journal of Clinical Oncology2017,8,4:7
3Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation显示文摘Acute humoral rejection (AHR) is uncommon after ABO-compatible liver transplantation. Herein, we report two cases of AHR treated with plasmapheresis and rituximab in two ABO-compatible liver-transplant patients with preformed anti-human leukocyte antigen donor-specif ic antibodies. Patient 1 experienced a biopsy-proven AHR at day 10 post-transplant. She was treated by steroid pulses, and OKT3. Because of persisting signs of biopsy-proven AHR at day 26, she was treated by plasmapheresis and rituximab. Liver enzyme levels did not improve, and she died on day 41. Patient 2 experienced a biopsy-proven AHR on day 10 post-transplant. She was treated by steroid pulses, plasmapheresis, and rituximab. Liver enzymes returned to within normal range 18 d after diagnosis. Liver biopsies, at 3 and 9 mo post-transplant, showed complete resolution of AHR. We conclude that plasmapheresis should be started as soon as AHR is diagnosed, and be associated with a B-cell depleting agent. Rituximab may be considered as a first-line therapy.Nassim Kamar Laurence Lavayssière Fabrice Muscari Janick Selves Céline Guilbeau-Frugier Isabelle Cardeau Laure Esposito Olivier Cointault Marie Béatrice Nogier Jean Marie Peron Philippe Otal Marylise Fort Lionel Rostaing 2009World Journal of Gastroenterology2009,15,27:6
4多器官床旁即时超声在新型冠状病毒肺炎中的应用:国际专家共识显示文摘新型冠状病毒肺炎(简称新冠肺炎,COVID-19)自首次报道以来,已造成全球超一亿人感染,给各国的公共卫生体系造成了巨大威胁。新冠肺炎的临床表现以呼吸系统体征和症状为主,80%的患者症状轻微,约5%为危重症患者,常表现为急性呼吸窘迫综合征(ARDS)。前期,由于缺乏相关研究,面对日益紧迫的临床困境,医务人员不得不借鉴采取一些经验性措施以应对疫情。王臻(译) Arif Hussain Gabriele Via Lawrence Melniker Alberto Goffi Guido Tavazzi Luca Neri Tomas Villen Richard Hoppmann Francesco Mojoli Vicki Noble Laurent Zieleskiewicz Pablo Blanco Irene W.Y.Ma Mahathar Abd.Wahab Abdulmohsen Alsaawi Majid AI Salamah Martin Balik Diego Barca Karim Bendjelid Belaid Bouhemad Pablo Bravo-Figueroa Raoul Breitkreutz Juan Calderon Jim Connolly Roberto Copetti Francesco Corradi Anthony J.Dean AndréDenault Deepak Govil Carmela Graci Young-Rock Ha Laura Hurtado Toru Kameda Michael Lanspa Christian B Laursen Francis Lee Rachel Liu Massimiliano Meineri Miguel Montorfano Peiman Nazerian Bret P.Nelson Aleksandar N.Neskovic Ramon Nogue Adi Osman JoséPazeli Elmo Pereira-Junior Tomislav Petrovic Emanuele Pivetta Jan Poelaert Susanna Price Gregor Prosen Shalim Rodriguez Philippe Rola Colin Royse Yale Tung Chen Mike Wells Adrian Wong Wang Xiaoting Wang Zhen Yaseen Arabi 2021中国呼吸与危重监护杂志2021,20,2:5
5Cobalt,a reactive metal in releasing hydrogen from sodium borohydride by hydrolysis:A short review and a research perspective显示文摘Cobalt is commonly admitted as being a promising catalyst in accelerating NaBH4 hydrolysis,being as reactive as noble metals and much more cost-effective.This is the topic of the present paper.Herein,we survey(i) the NaBH4-devoted literature while especially focusing on the Co catalysts and(ii) our work on the same topic.Finally,we report(iii) reactivity results of newly developed Co-based catalysts.From both surveys,it mainly stands out that Co has been investigated as catalysts in various forms:namely,as chlorides,reduced nanoparticles(metal Co,Co boride,Co-B alloy),supported over supports and shaped.In doing so the reactivity can be easily varied achieving H2 generation rates from few to >1000 L(H2)/min·g(metal).Nevertheless,our work can be distinguished from the NaBH4 literature.Indeed,we are working on strategies that focus on making alternative Co-based catalysts.One of these strategies is illustrated here as we report new reactivity data of Co-based bimetallic supported catalysts.For example,we show that 20 wt% Co90Y10/γAl2O3-20 wt% Co95Hf5/γAl2O3 > 20 wt% Co99Zr1/γAl2O3 > 20 wt% Co/γAl2O3,the best catalysts showing HGRs of about 245 mL(H2)/min or 123 L(H2) /min·g(metals).DEMIRCI Umit B AKDIM Ouardia HANNAUER Julien CHAMOUN Rita MIELE Philippe 2010Science China Chemistry2010,53,9:3
6Determination of several N-Methyl-D-Aspratate receptor blockers in plasma and brain by a selective high-performance liquid chromatographic method with column switching 显示文摘Ronald W Franz B Philipp W 1998J Chromatography A1998,797,:2
7Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study显示文摘Markus Ketteler Philipp Bongartz Ralf Westenfeld Joachim Ernst Wildberger Andreas Horst Mahnken Roland B?hm Thomas Metzger Christoph Wanner Willi Jahnen-Dechent Jürgen Floege 2003The Lancet2003,,9360:2
8Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol显示文摘Thomas Reiberger Gregor Ulbrich Arnulf Ferlitsch Berit Anna Payer Philipp Schwabl Matthias Pinter Birgit B Heinisch Michael Trauner Ludwig Kramer Markus Peck-Radosavljevic 2013Gut2013,,11:2
9Triayclglycerol Structure of Human Colostrum and Mature Milk 显示文摘Jean CM Philippe B 1993American Oil Chemists'' Society1993,28,7:1
10A haculovirus expression vector system for simultaneous protein expression in insect and mammalian cells 显示文摘Philipps B Forsmer M Mayr L M 2005Biotechnol Prog2005,21,3:1
11The 4+1 view model of architecture显示文摘 1995IEEE Software1995,12,6:1
12Nacylhomoserine lactones undergo lactonolysis in a pH-,temperature-,and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa显示文摘YATES E A PHILIPP B BUCKLEY C 2002Infect Immun2002,70,:1
13Noise Dressing of Financial Correlation Matrices 显示文摘PHILIPPE B MARC P 1999Physical Review Letters1999,83,7:1
14Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients.显示文摘Valerie M Philippe B Laetitia D 0,,:1
15Complete reversal of paraplegia after thoracic endovascular aortic repair in a patient with complicated acute aortic dissection using immediate cerebrospinal fluid drainage显示文摘Holger Eggebrecht Dirk B?se Thomas Gasser Jaroslav Benedik Petra Mummel Oliver Müller Philipp Kahlert Konstantinos Tsagakis Heinz G. Jakob Raimund Erbel 2009Clinical Research in Cardiology2009,,12:1
16Methane yield from switchgrass harvested at different stages of development in Eastern Canada显示文摘Daniel Massé Yan Gilbert Philippe Savoie Gilles Bélanger Gaétan Parent Daniel Babineau 2010Bioresource Technology2010,,24:1
17Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men,homosexual men and women:prevalence and associated factors显示文摘Laurent A Dalila B Philippe R 2007AIDS2007,21,11:1
18Biological treatment of ammoniumrich wastewater by partial nitrification and subsequent anaerobic ammonium oxidation(anammox)in a pilot plant显示文摘Christian F Marc B Philipp H 2002Journal of Biotechnology2002,99,3:1
19Biological treatment of ammonium-rich wastewater by partial nitrification and subsequent anaerobic ammonium oxidation (anammox) in a pilot plant显示文摘CHRISTIAN F MARC B PHILIPP H 2002Journal of Biotechnology2002,99,:1
20General considerations on structure and reactivity of cellulose显示文摘Klemm D Philipp B Heinze T 2004Comprehensive Cellulose Chemistry2004,12,3:1
返回顶部 每页显示:
共37页 首页 上一页 第1页 下一页 末页 /37 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费